Yesterday the World Health Organization (WHO) announced the approval of Bavarian Nordic's mpox vaccine, Jynneos, for adolescents aged 12 to 17.
The move comes as the outbreak in the Democratic Republic of the Congo is still raging, and infecting children at high rates.
Seroprevalence study suggests many unreported cases
In other mpox news, a new seroprevalence study from German researchers publishing in BMC Infectious Diseases shows a high proportion of clinically undiagnosed mpox among Berlin’s population of men who have sex with men (MSM.)
The study was conducted between April 11 and July 1, 2023, and included blood samples from 728 participants, who were recruited from eight private practices and two community-based checkpoints in Berlin.
Only 70 (7.4%) participants reported a previous diagnosis of mpox. However serological testing revealed an additional 91 individuals with suspected undiagnosed mpox infection.
Men who reported condomless sex with multiple partners were most likely to have mpox, and a substantial proportion of mpox infections were clinically undiagnosed, the authors said.
The authors said the findings were cautionary and suggest many more undiagnosed cases in MSM communities.
Many infections remain unrecognised and undiagnosed
"Mpox control measures based on clinical diagnosis of mpox are likely to have limited effectiveness in preventing mpox transmission in outbreak situations because many infections remain unrecognised and undiagnosed,” they concluded.